← The Wire
KRYSNasdaq
Krystal Biotech, Inc.
Biological Products, (No Diagnostic Substances) · CIK 1711279
Krystal Biotech develops and commercializes gene therapies for rare diseases like DEB, cystic fibrosis, and alpha-1 antitrypsin deficiency
⚡ Elevated coverage
$9.37B
Market cap
$378.15
Last close
+1.6%
1D
+10.1%
5D
287K
Volume
Price · last 39 sessions+31.8%
May 4L $284.57 · H $378.15Jun 29
190
Total filings
May 20, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteMay 20, 20268-KCompany UpdateMay 4, 202610-Q10-QMay 4, 2026DEFA14ADEFA14AApr 3, 2026DEF 14ADEF 14AApr 3, 20268-KResults of OperationsFeb 17, 202610-K10-KFeb 17, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KReg FD DisclosureJan 8, 20268-KExecutive ChangeDec 23, 20258-KResults of OperationsNov 3, 202510-Q10-QNov 3, 20258-KCompany UpdateOct 22, 20258-KResults of OperationsAug 4, 202510-Q10-QAug 4, 20258-KReg FD DisclosureJul 25, 20258-KReg FD DisclosureJul 24, 20258-KReg FD DisclosureJul 9, 20258-KCompany UpdateJun 2, 20258-KShareholder VoteMay 19, 20258-KReg FD DisclosureMay 13, 20258-KResults of OperationsMay 6, 202510-Q10-QMay 6, 20258-KReg FD DisclosureMay 6, 20258-KReg FD DisclosureApr 28, 2025DEFA14ADEFA14AApr 3, 2025DEF 14ADEF 14AApr 3, 20258-KCompany UpdateFeb 28, 20258-KReg FD DisclosureFeb 19, 202510-K10-KFeb 19, 20258-KReg FD DisclosureDec 18, 20248-KReg FD DisclosureDec 12, 202410-Q10-QNov 4, 20248-KResults of OperationsNov 4, 20248-KReg FD DisclosureAug 28, 202410-Q10-QAug 5, 20248-KResults of OperationsAug 5, 20248-KShareholder VoteMay 21, 20248-KReg FD DisclosureMay 8, 202410-Q10-QMay 6, 20248-KResults of OperationsMay 6, 2024DEFA14ADEFA14AApr 4, 2024DEF 14ADEF 14AApr 4, 20248-KResults of OperationsFeb 26, 202410-K10-KFeb 26, 2024SC 13GSCHEDULE 13GFeb 13, 20248-KResults of OperationsNov 6, 202310-Q10-QNov 6, 20238-KExecutive ChangeAug 7, 20238-KResults of OperationsAug 7, 202310-Q10-QAug 7, 20238-KReg FD DisclosureJul 26, 20238-KShareholder VoteMay 23, 20238-KMaterial Agreement · Equity IssuanceMay 22, 20238-KReg FD Disclosure · Company UpdateMay 19, 20238-KReg FD DisclosureMay 11, 20238-KMaterial AgreementMay 8, 2023424B5424B5May 8, 20238-KResults of OperationsMay 8, 202310-Q10-QMay 8, 20238-KReg FD DisclosureApr 24, 2023DEFA14ADEFA14AApr 4, 2023DEF 14ADEF 14AApr 4, 20238-KExecutive ChangeMar 6, 20238-KResults of OperationsFeb 27, 202310-K10-KFeb 27, 2023SC 13GKRYSTAL BIOTECH, INC.Feb 14, 20238-KReg FD DisclosureJan 9, 20238-KReg FD DisclosureNov 17, 20228-KResults of OperationsNov 7, 202210-Q10-QNov 7, 20228-KReg FD DisclosureNov 3, 20228-KReg FD Disclosure · Company UpdateAug 18, 20228-KResults of OperationsAug 8, 202210-Q10-QAug 8, 20228-KReg FD DisclosureJun 22, 20228-KAuditor ChangeMay 26, 20228-KShareholder VoteMay 23, 20228-KReg FD DisclosureMay 20, 20228-KResults of OperationsMay 9, 2022
Insider Activity
In the 90 days to Mar 4, 2026: 5 sold $63.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 8,798 | $264.85 | $2.3M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 6,000 | $265.16 | $1.6M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 4,852 | $264.64 | $1.3M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 3,667 | $260.37 | $955K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 3,128 | $260.49 | $815K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,962 | $261.41 | $774K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 2,931 | $261.41 | $766K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,439 | $265.59 | $648K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,380 | $262.44 | $625K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 2,248 | $263.58 | $593K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,043 | $263.70 | $539K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 1,938 | $262.35 | $508K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 1,700 | $266.42 | $453K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 1,377 | $259.87 | $358K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 920 | $266.56 | $245K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 668 | $259.61 | $173K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 589 | $258.54 | $152K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 483 | $257.31 | $124K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 470 | $258.38 | $121K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 407 | $257.32 | $105K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Investor's Business DailyStocks Jump As Trump Touts Iran Deal: SiTime, Krystal Biotech, Howmet In Focus18d agoInvestor's Business DailyDow Soars 600 Points As Oil, Bond Yields Plunge: Krystal Biotech, Morgan Stanley, Marriott In Focus1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance